HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

moxonidine (Moxon)

structure given in first source

Also Known As:

Moxon; Zint; Cynt; moxonidin; 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamine; BE 5895; BE-5895; Lilly brand of moxonidine; Normatens; Physiotens; Solvay brand of moxonidine

Networked: 232 relevant articles (37 outcomes, 48 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 60
- 1-Ring Heterocyclic Compounds
  - Azoles: 413
    - Imidazoles: 107
      - moxonidine: 232

Experts

1.	Mukaddam-Daher, Suhayla: 6 articles (10/2014 - 05/2005)
2.	Menani, José V: 5 articles (10/2011 - 06/2004)
3.	Medvedev, O S: 5 articles (11/2001 - 09/2000)
4.	Khokhlova, O N: 5 articles (11/2001 - 09/2000)
5.	El-Mas, Mahmoud M: 4 articles (08/2012 - 01/2009)
6.	Mohy El-Din, Mahmoud M: 4 articles (08/2012 - 01/2009)
7.	Ernsberger, Paul: 4 articles (08/2012 - 08/2003)
8.	Murashev, A N: 4 articles (11/2001 - 09/2000)
9.	De Luca, Laurival A: 3 articles (10/2011 - 11/2007)
10.	Mukaddam-Daher, S: 3 articles (10/2011 - 12/2003)

Related Diseases

1.	Hypertension (High Blood Pressure) 01/01/2006 - "Thus, moxonidine is a good option in the treatment of patients with mild to moderate hypertension, particularly as adjunctive therapy in patients with the metabolic syndrome." 08/01/2011 - "A 6-month clinical study with active therapeutic intervention was carried out to evaluate the efficacy of moxonidine for the correction of arterial hypertension in 30 patients with metabolic syndrome. " 08/01/2001 - "Moxonidine thus appears to be safe and effective antihypertensive drug in patients with essential hypertension." 01/01/2013 - "Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study." 01/01/2005 - "[Clinicogenetic aspects of carbohydrate metabolism disorders and efficacy of their correction with moxonidine and metformine in patients with arterial hypertension]."
2.	Insulin Resistance 12/01/1997 - "The sympatholytic antihypertensive agent moxonidine, a centrally acting selective I1-imidazoline receptor modulator (putative agonist), may be beneficial in hypertensive patients with insulin resistance. " 02/01/2007 - "Marked insulin resistance in obese spontaneously hypertensive rat adipocytes is ameliorated by in vivo but not in vitro treatment with moxonidine." 05/01/2004 - "It was thus considered of interest to investigate the effects of moxonidine, a centrally acting antihypertensive drug that reduces insulin resistance, in a rat model of preeclampsia. " 01/01/2000 - "Moxonidine has been shown to reduce left ventricular hypertrophy and is metabolically neutral; it may have a favourable effect on insulin resistance. " 01/01/1997 - "The I1-imidazoline receptor is a specific high-affinity binding site corresponding to a functional cell-surface receptor mediating the antihypertensive actions of moxonidine and other second-generation centrally-acting agents, and may play a role in countering insulin resistance in an animal model of metabolic syndrome X."
3.	Heart Failure 03/01/2006 - "Although beta-adrenergic blockade is beneficial in heart failure, inhibition of central sympathetic outflow using moxonidine has been associated with increased mortality. " 10/01/2003 - "The association between sympathetic activation and mortality in chronic heart failure and the favorable effect of beta blocking drugs has raised the possibility of therapeutic efficacy for central sympathetic inhibition with sustained-release (SR) moxonidine, an imidazoline receptor agonist. " 11/01/2013 - "Moxonidine-induced central sympathoinhibition attenuated brain oxidative stress, prevented cardiac dysfunction and remodelling, and improved the prognosis in rats with hypertensive heart failure. " 10/01/2003 - "Nonetheless, the excess early mortality and morbidity suggest the likelihood of an adverse effect of moxonidine SR and raise concerns regarding the efficacy of generalized sympathetic inhibition in heart failure." 11/01/2013 - "In the present study, we investigated the effects of central sympathoinhibition by intracerebral infusion of moxonidine on survival in a rat model of hypertensive heart failure and the possible mechanisms involved. "
4.	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 09/01/2012 - "The centrally-acting sympatholytic imidazoline compound, moxonidine, prevents the development of left ventricular hypertrophy and attenuates maladaptive proliferative signalling as well as downstream apoptotic pathways in spontaneously hypertensive rat and cardiomyopathic hamster hearts. " 08/01/1999 - "There is a regression of left-ventricular hypertrophy after moxonidine was given for 6 months. " 08/01/1997 - "Left ventricular hypertrophy has been found to regress after 6 months treatment with moxonidine. " 07/01/1997 - "Moxonidine showed a kidney-protective effect during the control diet measured as decreased urinary protein excretion, but it did not affect the development of left ventricular hypertrophy. " 01/01/2000 - "Moxonidine has been shown to reduce left ventricular hypertrophy and is metabolically neutral; it may have a favourable effect on insulin resistance. "
5.	Pain (Aches) 07/01/1999 - "Therefore, moxonidine may prove to be an effective treatment for pain with an improved side effect profile." 01/01/2000 - "Spinally administered moxonidine-opioid combinations may prove an effective therapeutic strategy to manage pain." 02/01/2001 - "Animal studies show that moxonidine may also be effective in pain and in ethanol withdrawal. " 01/01/2013 - "In conclusion, 4/6NX elicits high activity in central sympathetic, stress- and pain-related brain areas as well as in the limbic system, which can be ameliorated by losartan and particularly by moxonidine. " 10/01/2001 - "Moxonidine and radolmidine, which are not currently in clinical use in humans, may offer favorable side-effect profiles when compared with traditional alpha(2) agonists, and may thereby allow for more widespread pain management applications."

Related Drugs and Biologics

1.	Clonidine (ST 155)
2.	Insulin (Novolin)
3.	Atenolol (Tenormin)
4.	Norepinephrine (Noradrenaline)
5.	Cytokines
6.	Antihypertensive Agents (Antihypertensives)
7.	efaroxan
8.	Ethanol (Ethyl Alcohol)
9.	Adiponectin
10.	Imidazoline Receptors

Related Therapies and Procedures

1.	Ligation
2.	Injections
3.	Oral Administration
4.	Denervation
5.	Aftercare (After-Treatment)